StreetInsider.com News Articles

Form 8-K Genprex, Inc. For: Jul 13

Tue, 14 Jul 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260714/26766077.html

Form 8-K Genprex, Inc. For: Jul 13

Tue, 14 Jul 2026 09:23:00 -0400

si-local-file:///var/storage/secattach/20260714/26766077.html

Form S-8 Genprex, Inc.

Fri, 26 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260626/26699585.html

Form S-8 Genprex, Inc.

Fri, 26 Jun 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260626/26699585.html

Form 8-K Genprex, Inc. For: Jun 22

Mon, 22 Jun 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260622/26670803.html

Form 8-K Genprex, Inc. For: Jun 22

Mon, 22 Jun 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260622/26670803.html

Genprex receives Canadian patent notice for Reqorsa combo therapy

Mon, 22 Jun 2026 09:00:50 -0400

Genprex, Inc. (NASDAQ: GNPX) announced that the Canadian Intellectual Property Office has issued a Notice of Allowance for a patent covering the use of its Reqorsa Gene Therapy (quaratusugene ozeplasmid) in combination with either PD-1 or PD-L1 antibodies to treat non-small cell lung cancer and small cell lung cancer.

The Canadian patent expands Genprex's existing intellectual property portfolio, which already includes granted patents for the same combination in the U.S., Japan, Mexico, Russia, Chile, China, Singapore, Europe, Korea, Australia, and Israel.

The patent covers the therapeutic combination being evaluated in the company's Acclaim-3 clinical trial, a Phase 1/2 study assessing Reqorsa paired

Genprex receives Canadian patent notice for Reqorsa combo therapy

Mon, 22 Jun 2026 09:00:50 -0400

The patent covers the therapeutic combination being evaluated in the company's Acclaim-3 clinical trial, a Phase 1/2 study assessing Reqorsa paired

Genprex receives Canadian patent notice for Reqorsa combo therapy

Mon, 22 Jun 2026 09:00:50 -0400

The patent covers the therapeutic combination being evaluated in the company's Acclaim-3 clinical trial, a Phase 1/2 study assessing Reqorsa paired

Genprex receives Canadian patent notice for Reqorsa combo therapy

Mon, 22 Jun 2026 09:00:50 -0400

The patent covers the therapeutic combination being evaluated in the company's Acclaim-3 clinical trial, a Phase 1/2 study assessing Reqorsa paired

Genprex receives Canadian patent notice for Reqorsa combo therapy

Mon, 22 Jun 2026 09:00:50 -0400

The patent covers the therapeutic combination being evaluated in the company's Acclaim-3 clinical trial, a Phase 1/2 study assessing Reqorsa paired

Genprex receives Canadian patent notice for Reqorsa combo therapy

Mon, 22 Jun 2026 09:00:50 -0400

The patent covers the therapeutic combination being evaluated in the company's Acclaim-3 clinical trial, a Phase 1/2 study assessing Reqorsa paired

Genprex receives Canadian patent notice for Reqorsa combo therapy

Mon, 22 Jun 2026 09:00:50 -0400

The patent covers the therapeutic combination being evaluated in the company's Acclaim-3 clinical trial, a Phase 1/2 study assessing Reqorsa paired

Genprex receives Canadian patent notice for Reqorsa combo therapy

Mon, 22 Jun 2026 09:00:50 -0400

The patent covers the therapeutic combination being evaluated in the company's Acclaim-3 clinical trial, a Phase 1/2 study assessing Reqorsa paired

Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Canc

Mon, 22 Jun 2026 09:00:00 -0400